Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, February 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 150 articles:
HTML format


 

Single Articles

  1. YE W, Chen C, Gao Y, Zheng ZS, et al
    Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity.
    Cell Death Dis. 2017;8:e2581.
    Abstract    

    Abstract available

  2. ZARGAR H, Almassi N, Kovac E, Ercole C, et al
    Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:57-63.
    Abstract    

    Abstract available

  3. MATULEWICZ RS, DeLancey JO, Pavey E, Schaeffer EM, et al
    Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer.
    Bladder Cancer. 2017;3:45-49.
    Abstract    

    Abstract available

  4. VON RUNDSTEDT FC, Mata DA, Kryvenko ON, Shah AA, et al
    Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.
    Bladder Cancer. 2017;3:35-44.
    Abstract    

    Abstract available

  5. BAUMANN BC, Sargos P, Eapen LJ, Efstathiou JA, et al
    The Rationale for Post-Operative Radiation in Localized Bladder Cancer.
    Bladder Cancer. 2017;3:19-30.
    Abstract    

    Abstract available

  6. FRANTZI M, Vlahou A
    Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.
    Bladder Cancer. 2017;3:1-18.
    Abstract    

    Abstract available

  7. VERMA A, Kapoor R, Mittal RD
    Cluster of Differentiation 44 (CD44) Gene Variants: A Putative Cancer Stem Cell Marker in Risk Prediction of Bladder Cancer in North Indian Population.
    Indian J Clin Biochem. 2017;32:74-83.
    Abstract    

    Abstract available

  8. HADAMI K, Ameziane El Hassani R, Ameur A, Dakka N, et al
    Association between GPX1 Pro189Leu polymorphism and the occurrence of bladder cancer in Morocco.
    Cell Mol Biol (Noisy-le-grand). 2016;62:38-43.
    Abstract    

    Abstract available

  9. WILDE L, Ali SM, Solomides CC, Ross JS, et al
    Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
    Clin Genitourin Cancer. 2016 Dec 22. pii: S1558-7673(16)30358.
    Abstract    



  10. WU Y, Zhang X, Li Z, Yan H, et al
    Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN.
    Food Funct. 2017 Jan 31. doi: 10.1039/c6fo01535.
    Abstract    

    Abstract available

  11. CUI X, Shen D, Kong C, Zhang Z, et al
    NF-kappaB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.
    Sci Rep. 2017;7:40723.
    Abstract    

    Abstract available

  12. LEE D, Yoo S, You D, Hong B, et al
    Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy.
    Urol Oncol. 2017 Jan 27. pii: S1078-1439(16)30366.
    Abstract    

    Abstract available

  13. TAO S, Meng S, Zheng X, Xie L, et al
    ATM participates in the regulation of viability and cell cycle via ellipticine in bladder cancer.
    Mol Med Rep. 2017 Jan 24. doi: 10.3892/mmr.2017.6141.
    Abstract    

    Abstract available

  14. BUTTIGLIERO C, Tucci M, Vignani F, Scagliotti GV, et al
    Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.
    Cancer Treat Rev. 2017;54:1-9.
    Abstract    

    Abstract available

  15. ASAI K, Murata M, Saso K, Yamada M, et al
    [A Case of Metachronous Liver Metastases of Gall Bladder Cancer Successfully Treated by Liver Resection].
    Gan To Kagaku Ryoho. 2016;43:2092-2094.
    Abstract    

    Abstract available

  16. ABBAOUI B, Telu KH, Lucas CR, Thomas-Ahner JM, et al
    The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.
    J Proteomics. 2017 Jan 26. pii: S1874-3919(17)30026.
    Abstract    

    Abstract available

  17. LIU D, Plimack ER, Hoffman-Censits J, Garraway LA, et al
    Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
    JAMA Oncol. 2016;2:1094-6.
    Abstract    



  18. LI J, Wang P, Wang B
    Unique Case Report of Pineal Gland Metastasis From Bladder Carcinoma.
    Medicine (Baltimore). 2016;95:e3622.
    Abstract    

    Abstract available

  19. LIEDBERG F, Hoglund M
    [Not Available].
    Lakartidningen. 2016;113.
    Abstract    



  20. OGAWA Y
    Chemical poisonings, new and old.
    Ind Health. 2016;54:99-100.
    Abstract    



  21. ALLEEMUDDER DI, Alleemudder AI, Harry D, Fountain S, et al
    Bladder squamous cell carcinoma in pregnancy.
    J Obstet Gynaecol. 2016;36:388-9.
    Abstract    



  22. XU WJ, Wen LP, Jiang XX, Ye LY, et al
    Association between N-Acetyltransferase 2 Polymorphism and Bladder Cancer Risk: a Meta-Analysis in a Single Ethnic Group.
    Clin Lab. 2017;63:287-293.
    Abstract    

    Abstract available

  23. HUI K, Gao Y, Huang J, Xu S, et al
    RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
    Cell Death Dis. 2017;8:e2600.
    Abstract    

    Abstract available

  24. PANEBIANCO V, De Berardinis E, Barchetti G, Simone G, et al
    An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer.
    Eur Radiol. 2017 Feb 8. doi: 10.1007/s00330-017-4758.
    Abstract    

    Abstract available

  25. YANG Y, Li C, Li H, Wu M, et al
    Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile.
    Oncotarget. 2017 Feb 2. doi: 10.18632/oncotarget.15041.
    Abstract    

    Abstract available

  26. DONG Q, Fu L, Zhao Y, Tan S, et al
    Derlin-1 overexpression confers poor prognosis in muscle invasive bladder cancer and contributes to chemoresistance and invasion through PI3K/AKT and ERK/MMP signaling.
    Oncotarget. 2017 Feb 2. doi: 10.18632/oncotarget.15001.
    Abstract    

    Abstract available


  27. Bladder cancer: Risk factors, diagnosis, and management.
    Nurse Pract. 2017;42:33-34.
    Abstract    



  28. SHIN SS, Won SY, Noh DH, Hwang B, et al
    Morin Inhibits Proliferation, Migration, and Invasion of Bladder Cancer EJ Cells via Modulation of Signaling Pathways, Cell Cycle Regulators, and Transcription Factor-Mediated MMP-9 Expression.
    Drug Dev Res. 2017 Feb 8. doi: 10.1002/ddr.21377.
    Abstract    

    Abstract available

  29. FARLING KB
    Bladder cancer: Risk factors, diagnosis, and management.
    Nurse Pract. 2017;42:26-33.
    Abstract    

    Abstract available

  30. LEE M, Shin SJ, Oh YT, Jung DC, et al
    Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion.
    Eur Radiol. 2017 Feb 6. doi: 10.1007/s00330-017-4759.
    Abstract    

    Abstract available

  31. PIRZADA MT, Ghauri R, Ahmed MJ, Shah MF, et al
    Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study.
    Cureus. 2017;9:e957.
    Abstract    

    Abstract available

  32. WENG H, Zeng XT, Li S, Kwong JS, et al
    Tea Consumption and Risk of Bladder Cancer: A Dose-Response Meta-Analysis.
    Front Physiol. 2017;7:693.
    Abstract    

    Abstract available

  33. OLKHOV-MITSEL E, Savio AJ, Kron KJ, Pethe VV, et al
    Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.
    Transl Oncol. 2017;10:168-177.
    Abstract    

    Abstract available

  34. KANG M, Lee KH, Lee HS, Jeong CW, et al
    Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  35. MANIKANDAN R, Rodriguez O, Parada R, Palou Redorta J, et al
    Nonmuscle-invasive bladder cancer: what's changing and what has changed.
    Urologia. 2017;84:1-8.
    Abstract    

    Abstract available

  36. YANG D, Huo Q, Luan T, Wang J, et al
    Effects of Angiotensin Inhibitor Valsartan on the Expression of the Angiotensin II 1 Receptor, Matrix Metalloproteinases -2 and -9 in Human Bladder Cancer Cell Lines.
    Clin Lab. 2016;62:1435-1442.
    Abstract    

    Abstract available

  37. THONG AE, Petruzella S, Orlow I, Zabor EC, et al
    Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center.
    Eur Urol Focus. 2016;2:441-444.
    Abstract    

    Abstract available

  38. FEBER A, Dhami P, Dong L, de Winter P, et al
    UroMark-a urinary biomarker assay for the detection of bladder cancer.
    Clin Epigenetics. 2017;9:8.
    Abstract    

    Abstract available

  39. KANG M, Balpukov UJ, Jeong CW, Kwak C, et al
    Can the Preoperative Neutrophil-to-Lymphocyte Ratio Significantly Predict the Conditional Survival Probability in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy?
    Clin Genitourin Cancer. 2017 Jan 9. pii: S1558-7673(16)30324.
    Abstract    

    Abstract available

  40. ZHOU Y, Song R, Ma C, Zhou L, et al
    Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14988.
    Abstract    

    Abstract available

  41. CHEN M, Li J, Zhuang C, Cai Z, et al
    Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer.
    Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14945.
    Abstract    

    Abstract available

  42. NAKAMURA T, Noma Y, Sakurai Y, Harashima H, et al
    Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells.
    Biol Pharm Bull. 2017;40:234-237.
    Abstract    

    Abstract available

  43. RAMAN SP, Fishman EK
    Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography.
    Radiol Clin North Am. 2017;55:225-241.
    Abstract    

    Abstract available

  44. STROJAN FLEZAR M, Srebotnik-Kirbis I, Gutnik H
    Use of vimentin immunocytochemical staining for evaluation of atypical cells in voided urine samples.
    Diagn Cytopathol. 2017;45:85-90.
    Abstract    

    Abstract available

  45. LI X, Liu S
    Suppression of HBXIP Reduces Cell Proliferation, Migration and Invasion In Vitro, and Tumorigenesis In Vivo in Human Urothelial Carcinoma of the Bladder.
    Cancer Biother Radiopharm. 2016;31:311-316.
    Abstract    

    Abstract available

  46. SHEN KH, Li CF, Chien LH, Huang CH, et al
    Role of galectin-1 in urinary bladder urothelial carcinoma cell invasion through the JNK pathway.
    Cancer Sci. 2016;107:1390-1398.
    Abstract    

    Abstract available

  47. DE ALMEIDA EF, Abdalla TE, Arrym TP, de Oliveira Delgado P, et al
    Plasma and urine DNA levels are related to microscopic hematuria in patients with bladder urothelial carcinoma.
    Clin Biochem. 2016;49.
    Abstract    

    Abstract available

  48. KURTZHALTS K, Gee ME, Feuz L, Krajewski KC, et al
    Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
    Am J Health Syst Pharm. 2016;73:1508-11.
    Abstract    

    Abstract available

  49. LIN DM, Park JW, Gattuso P
    Metastatic Signet-Ring Cell Carcinoma of the Bladder in Cerebrospinal Fluid.
    Diagn Cytopathol. 2017;45:73-76.
    Abstract    

    Abstract available

  50. ZHAO XR, Gao C, Zhang Y, Kong L, et al
    Urachal adenocarcinoma that metastasized to breast was misinterpreted as primary breast mucinous carcinoma: A rare case report and literature review.
    Medicine (Baltimore). 2016;95:e4612.
    Abstract    

    Abstract available

  51. KIM TK, Xu ML, Podoltsev NA, Prebet T, et al
    Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2016.
    Abstract    



  52. XIN J, Lai HP, Lin SK, Zhang QQ, et al
    Bladder leiomyoma presenting as dyspareunia: Case report and literature review.
    Medicine (Baltimore). 2016;95:e3971.
    Abstract    

    Abstract available

  53. ALBERTI C
    Urology pertinent neuroendocrine tumors: focusing on renal pelvis, bladder, prostate located sympathetic functional paragangliomas.
    G Chir. 2016;37:55-60.
    Abstract    

    Abstract available

  54. GOLDMAN H, Sowter S
    Urachal adenocarcinoma incidentally discovered in a young woman at elective caesarean section.
    BMJ Case Rep. 2016;2016.
    Abstract    

    Abstract available

  55. KONG YG, Kim JY, Yu J, Lim J, et al
    Efficacy and Safety of Stroke Volume Variation-Guided Fluid Therapy for Reducing Blood Loss and Transfusion Requirements During Radical Cystectomy: A Randomized Clinical Trial.
    Medicine (Baltimore). 2016;95:e3685.
    Abstract    

    Abstract available

  56. GONZALEZ-DEL VECCHIO M, Ruiz-Serrano MJ, Gijon P, Sanchez-Somolinos M, et al
    Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital.
    Diagn Microbiol Infect Dis. 2016;85:338-43.
    Abstract    

    Abstract available

  57. LI WM, Wei YC, Huang CN, Ke HL, et al
    Matrix metalloproteinase-11 as a marker of metastasis and predictor of poor survival in urothelial carcinomas.
    J Surg Oncol. 2016;113:700-7.
    Abstract    

    Abstract available

  58. WENG WC, Huang YH, Yang SF, Wang SS, et al
    Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.
    Tumour Biol. 2016;37:6971-7.
    Abstract    

    Abstract available

  59. SCHUBERT M, Junker K, Heinzelmann J
    Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
    J Cancer Res Clin Oncol. 2016;142:1673-95.
    Abstract    

    Abstract available

  60. STEINESTEL K, Eder S, Ehinger K, Schneider J, et al
    The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.
    Tumour Biol. 2016;37:6275-83.
    Abstract    

    Abstract available

  61. NOLAN CP, Forde EJ
    A review of the use of fiducial markers for image-guided bladder radiotherapy.
    Acta Oncol. 2016;55:533-8.
    Abstract    

    Abstract available

  62. JAEGER MT, Siemens DR, Wei X, Peng P, et al
    Association Between Anesthesiology Volumes and Early and Late Outcomes After Cystectomy for Bladder Cancer: A Population-Based Study.
    Anesth Analg. 2017 Feb 15. doi: 10.1213/ANE.0000000000001781.
    Abstract    

    Abstract available

  63. ZHAN L, Zhang B, Tan Y, Yang C, et al
    Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
    Medicine (Baltimore). 2017;96:e6097.
    Abstract    

    Abstract available

  64. SHAO YH, Kao CC, Tang SH, Cha TL, et al
    Unusual presentation of direct intraperitoneal metastases complicated with massive ascites from plasmacytoid variant of bladder cancer and adenocarcinoma of colon: A case report and literature review.
    Medicine (Baltimore). 2017;96:e5816.
    Abstract    

    Abstract available

  65. FU D, Li P, Cheng W, Tian F, et al
    Impact of vascular endothelial growth factor gene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population.
    Oncotarget. 2017 Feb 11. doi: 10.18632/oncotarget.15287.
    Abstract    

    Abstract available

  66. KISS B, Wyatt AW, Douglas J, Skuginna V, et al
    Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.
    Sci Rep. 2017;7:42713.
    Abstract    

    Abstract available

  67. WANG CY, Hua R, Liu L, Zhan X, et al
    Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
    Cancer Med. 2017 Feb 16. doi: 10.1002/cam4.1023.
    Abstract    

    Abstract available

  68. MATSUDA T, Okuyama A
    Incidence rate for bladder cancer in Japanese in Japan and in the United States from the Cancer Incidence in Five Continents.
    Jpn J Clin Oncol. 2017 Feb 16:1-2. doi: 10.1093.
    Abstract    



  69. PEI Z, Du X, Song Y, Fan L, et al
    Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/beta-catenin signaling pathway.
    Oncotarget. 2017 Feb 9. doi: 10.18632/oncotarget.15210.
    Abstract    

    Abstract available

  70. ZHANG X, Xu X, Tian Q, Li B, et al
    Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging.
    J Magn Reson Imaging. 2017 Feb 15. doi: 10.1002/jmri.25669.
    Abstract    

    Abstract available

  71. DOMINGOS-PEREIRA S, Cesson V, Chevalier MF, Derre L, et al
    Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.
    Oncoimmunology. 2016;6:e1265720.
    Abstract    

    Abstract available

  72. SMITH SG, Baltz JL, Koppolu BP, Ravindranathan S, et al
    Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer.
    Oncoimmunology. 2016;6:e1259050.
    Abstract    

    Abstract available

  73. BETTIGA A, Aureli M, Colciago G, Murdica V, et al
    Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism.
    Sci Rep. 2017;7:42157.
    Abstract    

    Abstract available

  74. GUPTA S, De S, Leekha N, Sahay SC, et al
    Chemoradiation for organ preservation in the treatment of muscle invasive bladder cancer: Our Institutional Experience.
    Gulf J Oncolog. 2016;1:55-60.
    Abstract    

    Abstract available

  75. RICHARD PO, Ahmad AE, Bashir S, Hamilton RJ, et al
    Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: A population-based analysis.
    Urol Oncol. 2017 Feb 9. pii: S1078-1439(16)30417.
    Abstract    

    Abstract available

  76. TRAINOR S, Choudhury A, Huddart R, Kiltie AE, et al
    The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?
    Clin Oncol (R Coll Radiol). 2017 Feb 9. pii: S0936-6555(17)30068.
    Abstract    



  77. BUSETTO GM, Ferro M, Del Giudice F, Antonini G, et al
    The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2017 Jan 18. pii: S1558-7673(17)30011.
    Abstract    

    Abstract available

  78. SARGOS P, Larre S, Chapet O, Latorzeff I, et al
    [Adjuvant radiotherapy for bladder cancer in patients with risk of locoregional recurrence: Who, what and how?]
    Cancer Radiother. 2017 Feb 7. pii: S1278-3218(17)30004.
    Abstract    

    Abstract available

  79. DONG F, Xu T, Shen Y, Zhong S, et al
    Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure.
    Oncotarget. 2017 Feb 7. doi: 10.18632/oncotarget.15173.
    Abstract    

    Abstract available

  80. REZAEI G, Habibi-Anbouhi M, Mahmoudi M, Azadmanesh K, et al
    Development of anti-CD47 single-chain variable fragment targeted magnetic nanoparticles for treatment of human bladder cancer.
    Nanomedicine (Lond). 2017 Feb 10. doi: 10.2217/nnm-2016-0302.
    Abstract    

    Abstract available

  81. UKAI R, Hashimoto K, Nakayama H, Iwamoto T, et al
    Lymphovascular invasion predicts poor prognosis in high-grade pT1 bladder cancer patients who underwent transurethral resection in one piece.
    Jpn J Clin Oncol. 2017 Feb 10:1-6. doi: 10.1093.
    Abstract    




  82. Nivolumab Gets FDA Nod for Bladder Cancer.
    Cancer Discov. 2017 Feb 9. doi: 10.1158/2159-8290.CD-NB2017.
    Abstract    

    Abstract available

  83. AOUN F, El Rassy E, Peltier A
    Bladder cancer immunotherapy: swinging for the fences.
    Future Oncol. 2017 Feb 10. doi: 10.2217/fon-2017-0013.
    Abstract    



  84. SOLINAS C, Chanza NM, Awada A, Scartozzi M, et al
    The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.
    Cancer Treat Rev. 2017;53:138-145.
    Abstract    

    Abstract available

  85. SU X, Fang D, Li X, Xiong G, et al
    The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.
    Biomed Res Int. 2016;2016:4368943.
    Abstract    

    Abstract available

  86. PATEL R, Bock M, Polotti CF, Elsamra S, et al
    Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Expert Opin Drug Metab Toxicol. 2017;13:225-232.
    Abstract    

    Abstract available

  87. GRAPIN-DAGORNO C, Peycelon M, Philippe-Chomette P, Berrebi D, et al
    [Urothelial tumors in children].
    Bull Cancer. 2017;104:195-201.
    Abstract    

    Abstract available

  88. MANLEY KV, Hubbard R, Swallow D, Finch W, et al
    Risk factors for development of primary bladder squamous cell carcinoma.
    Ann R Coll Surg Engl. 2017;99:155-160.
    Abstract    

    Abstract available

  89. GRANADOS R, Duarte JA, Corrales T, Camarmo E, et al
    Applying the Paris System for Reporting Urine Cytology Increases the Rate of Atypical Urothelial Cells in Benign Cases: A Need for Patient Management Recommendations.
    Acta Cytol. 2017;61:71-76.
    Abstract    

    Abstract available

  90. BREYER J, Wirtz RM, Laible M, Schlombs K, et al
    ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).
    Virchows Arch. 2016;469:547-552.
    Abstract    

    Abstract available

  91. SHANMUGAM V, Geraghty B, DeSimone R, Hoda RS, et al
    Diagnostic value of positive urinary cytology in the detection of recurrent urothelial carcinoma: 10-Year Experience at the Papanicolaou Cytology Laboratory.
    Diagn Cytopathol. 2016 Sep 26. doi: 10.1002/dc.23598.
    Abstract    

    Abstract available

  92. PRABHU B, Balakrishnan D, Sundaresan S
    Antiproliferative and anti-inflammatory properties of diindolylmethane and lupeol against N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder carcinogenesis in experimental rats.
    Hum Exp Toxicol. 2016;35:685-92.
    Abstract    

    Abstract available

  93. DE OLIVEIRA DT, Savio AL, Marcondes JP, Barros TM, et al
    Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.
    J Biosci. 2017;42:91-101.
    Abstract    

    Abstract available

  94. TANG M, Zhao Y, Liu N, Chen E, et al
    Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway.
    J Cancer Res Clin Oncol. 2017 Feb 22. doi: 10.1007/s00432-016-2333.
    Abstract    

    Abstract available

  95. TEKE K, Ozkan TA, Cebeci OO, Yilmaz H, et al
    Preventive effect of intravesical ozone supplementation on n-methyl-n-nitrosourea-induced non-muscle invasive bladder cancer in male rats.
    Exp Anim. 2017 Feb 22. doi: 10.1538/expanim.16-0093.
    Abstract    

    Abstract available

  96. LER LD, Ghosh S, Chai X, Thike AA, et al
    Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
    Sci Transl Med. 2017;9.
    Abstract    

    Abstract available

  97. JIANG G, Huang C, Li J, Huang H, et al
    Role of STAT3 and FOXO1 in the divergent therapeutic responses of non-metastatic and metastatic bladder cancer cells to miR-145.
    Mol Cancer Ther. 2017 Feb 21. pii: molcanther.0631.2016.
    Abstract    

    Abstract available

  98. GUO J, Cao R, Yu X, Xiao Z, et al
    MicroRNA-223-3p inhibits human bladder cancer cell migration and invasion.
    Tumour Biol. 2017;39:1010428317691678.
    Abstract    

    Abstract available

  99. ZHI Y, Ji H, Pan J, He P, et al
    Downregulated XPA promotes carcinogenesis of bladder cancer via impairment of DNA repair.
    Tumour Biol. 2017;39:1010428317691679.
    Abstract    

    Abstract available

  100. LI P, Yang X, Cheng Y, Zhang X, et al
    MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1.
    Cell Physiol Biochem. 2017;41:921-932.
    Abstract    

    Abstract available

  101. POZZAR RA, Berry DL
    Gender Differences in Bladder Cancer Treatment Decision Making.
    Oncol Nurs Forum. 2017;44:204-209.
    Abstract    

    Abstract available


  102. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther. 2017;59:e40-e41.
    Abstract    



  103. SIDAWAY P
    Bladder cancer: Mutations in DNA-damage-repair pathways confer platinum sensitivity.
    Nat Rev Urol. 2017 Feb 14. doi: 10.1038/nrurol.2017.
    Abstract    



  104. DEMIRDAG C, Citgez S, Talat Z, Onal B, et al
    Management of Bladder Cancer After Renal Transplantation.
    Transplant Proc. 2017;49:293-296.
    Abstract    

    Abstract available

  105. EL-ASHMAWY NE, Khedr EG, El-Bahrawy HA, Al-Tantawy SM, et al
    Chemopreventive effect of omega-3 polyunsaturated fatty acids and atorvastatin in rats with bladder cancer.
    Tumour Biol. 2017;39:1010428317692254.
    Abstract    

    Abstract available

  106. XU X, Liu Y, Zhang X, Tian Q, et al
    Preoperative prediction of muscular invasiveness of bladder cancer with radiomic features on conventional MRI and its high-order derivative maps.
    Abdom Radiol (NY). 2017 Feb 20. doi: 10.1007/s00261-017-1079.
    Abstract    

    Abstract available

  107. CANYILMAZ E, Yoney A, Serdar L, Uslu GH, et al
    Corrigendum to "Long-term results of a concomitant boost radiotherapy technique for elderly patients with muscle-invasive bladder cancer" [J Geriatr Oncol6 (4) (July 2015)316-323].
    J Geriatr Oncol. 2017 Feb 16. pii: S1879-4068(17)30026.
    Abstract    



  108. BELLMUNT J, Powles T, Vogelzang NJ
    A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Cancer Treat Rev. 2017;54:58-67.
    Abstract    

    Abstract available

  109. ABUFARAJ M, Shariat SF, Haitel A, Moschini M, et al
    Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Urol Oncol. 2017 Feb 14. pii: S1078-1439(17)30014.
    Abstract    

    Abstract available

  110. EDMONDSON AJ, Birtwistle JC, Catto JW, Twiddy M, et al
    The patients' experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence.
    J Cancer Surviv. 2017 Feb 17. doi: 10.1007/s11764-017-0603.
    Abstract    

    Abstract available

  111. LIN T, Yuan A, Zhao X, Lian H, et al
    Self-assembled tumor-targeting hyaluronic acid nanoparticles for photothermal ablation in orthotopic bladder cancer.
    Acta Biomater. 2017 Feb 14. pii: S1742-7061(17)30126.
    Abstract    

    Abstract available

  112. INGELMO-TORRES M, Lozano JJ, Izquierdo L, Carrion A, et al
    Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer.
    Oncotarget. 2017 Feb 14. doi: 10.18632/oncotarget.15315.
    Abstract    

    Abstract available

  113. GENG J, Fan J, Wang Q, Zhang XP, et al
    Decreased REG1alpha expression suppresses growth, invasion and angiogenesis of bladder cancer.
    Eur J Surg Oncol. 2017 Feb 2. pii: S0748-7983(17)30108.
    Abstract    

    Abstract available

  114. PATEL S, Hafez O, Sexton WJ, Edwards DA, et al
    Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.
    A A Case Rep. 2017;8:78-80.
    Abstract    

    Abstract available

  115. LIU Y, Bui MM, Xu B
    Urothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis.
    Cancer Control. 2017;24:78-82.
    Abstract    

    Abstract available

  116. COURTADE-SAIDI M, Aziza J, d'Aure D, Berard E, et al
    Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.
    Cytopathology. 2016;27:456-464.
    Abstract    

    Abstract available

  117. VAN DE GOOR RM, Leunis N, van Hooren MR, Francisca E, et al
    Feasibility of electronic nose technology for discriminating between head and neck, bladder, and colon carcinomas.
    Eur Arch Otorhinolaryngol. 2017;274:1053-1060.
    Abstract    

    Abstract available

  118. XU X, Wei M, Liu Y, Liu X, et al
    A simple, fast, label-free colorimetric method for detection of telomerase activity in urine by using hemin-graphene conjugates.
    Biosens Bioelectron. 2017;87:600-606.
    Abstract    

    Abstract available

  119. KISHIMOTO N, Takao T, Kuribayashi S, Yamamichi G, et al
    The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
    Int J Clin Oncol. 2017;22:153-158.
    Abstract    

    Abstract available

  120. NGUYEN D, Taheri D, Springer S, Cowan M, et al
    High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Virchows Arch. 2016;469:427-34.
    Abstract    

    Abstract available

  121. VOLLMER RT
    A Review of Outcomes for Stage Ta Bladder Tumors.
    Am J Clin Pathol. 2016;146:215-20.
    Abstract    

    Abstract available

  122. SMITH DM
    BCG-osis following intravesical BCG treatment leading to miliary pulmonary nodules, penile granulomas and a mycotic aortic aneurysm.
    BMJ Case Rep. 2016;2016.
    Abstract    

    Abstract available

  123. ZHOU AG, Liu Y, Cyr MS, Garver J, et al
    Role of Tetrasomy for the Diagnosis of Urothelial Carcinoma Using UroVysion Fluorescent In Situ Hybridization.
    Arch Pathol Lab Med. 2016;140:552-9.
    Abstract    

    Abstract available

  124. PHAM HV, Pantanowitz L, Liu Y
    Quantitative phase imaging to improve the diagnostic accuracy of urine cytology.
    Cancer Cytopathol. 2016;124:641-50.
    Abstract    

    Abstract available

  125. ROSENTHAL DL
    High apoptotic index in urine cytology is associated with high-grade urothelial carcinoma.
    Cancer Cytopathol. 2016;124:538-9.
    Abstract    



  126. YANG CS, Chen S, Cramer HM, Wu HH, et al
    High apoptotic index in urine cytology is associated with high-grade urothelial carcinoma.
    Cancer Cytopathol. 2016;124:546-51.
    Abstract    

    Abstract available

  127. SANFRANCESCO J, McKenney JK, Leivo MZ, Gupta S, et al
    Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.
    Arch Pathol Lab Med. 2016;140:543-51.
    Abstract    

    Abstract available

  128. ZHANG ML, Rosenthal DL, VandenBussche CJ
    The cytomorphological features of low-grade urothelial neoplasms vary by specimen type.
    Cancer Cytopathol. 2016;124:552-64.
    Abstract    

    Abstract available

  129. LOVDAHL S, Henriksson KM, Baghaei F, Holmstrom M, et al
    Malignancies in Swedish persons with haemophilia: a longitudinal registry study.
    Blood Coagul Fibrinolysis. 2016;27:631-6.
    Abstract    

    Abstract available

  130. BRIMO F, Auger M
    The atypical urothelial cell category in the Paris System: Strengthening the Achilles' heel.
    Cancer Cytopathol. 2016;124:305-6.
    Abstract    



  131. MANIG L, Kasmann L, Janssen S, Rades D, et al
    Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.
    Anticancer Res. 2016;36:6663-6665.
    Abstract    

    Abstract available

  132. HANCOCK BM, McGuire KL, Tsuji S, Reil K, et al
    A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
    Anticancer Res. 2016;36:6243-6248.
    Abstract    

    Abstract available

  133. WIECZOREK E, Jablonowski Z, Tomasik B, Gromadzinska J, et al
    Different Gene Expression and Activity Pattern of Antioxidant Enzymes in Bladder Cancer.
    Anticancer Res. 2017;37:841-848.
    Abstract    

    Abstract available

  134. IWAMOTO H, Izumi K, Shimura Y, Natsagdorj A, et al
    Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.
    Anticancer Res. 2016;36:5557-5561.
    Abstract    

    Abstract available

  135. VESKIMAE E, Neuzillet Y, Rouanne M, MacLennan S, et al
    Systematic review of the oncological and functional outcomes of pelvic organ-preserving cystectomy compared with standard radical cystectomy in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13819.
    Abstract    

    Abstract available

  136. SIN ML, Mach KE, Sinha R, Wu F, et al
    Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.2610.2016.
    Abstract    

    Abstract available

  137. KAWADA T
    Bladder cancer and smoking with special reference to education.
    Eur J Cancer. 2017;75:1-2.
    Abstract    



  138. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    Abstract    



  139. INOUE K
    5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
    Int J Urol. 2017;24:97-101.
    Abstract    

    Abstract available

  140. KUSHI LH, Quinn VP, Ghai NR, Roh JM, et al
    Identifying lifestyle and genetic factors to prevent recurrence of non-muscle invasive bladder cancer in a prospective cohort study at Kaiser Permanente (the Be-Well study).
    J Clin Oncol. 2016;34.
    Abstract    

    Abstract available

  141. DANFORTH KN, Kwan ML, Bulkley JE, O'Keeffe-Rosetti MC, et al
    Recovery challenges faced by bladder cancer survivors after recent cystectomy and urinary diversion.
    J Clin Oncol. 2016;34.
    Abstract    

    Abstract available

  142. STEINBERG GD
    Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Gr
    J Urol. 2017 Feb 6. pii: S0022-5347(16)32070-5. doi: 10.1016/j.juro.2016.
    Abstract    



  143. CHANG SS
    Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer.
    J Urol. 2017;197.
    Abstract    



  144. LI W, Liu J, Zou D, Cai X, et al
    Exploration of bladder cancer molecular mechanisms based on miRNA-mRNA regulatory network.
    Oncol Rep. 2017;37:1461-1468.
    Abstract    

    Abstract available

  145. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    Abstract    

    Abstract available

  146. ROBINS DJ, Sui W, Matulay JT, Ghandour R, et al
    Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Nonmuscle Invasive Bladder Cancer after Previous Bacillus Calmette-Guerin Therapy.
    Urology. 2017 Feb 2. pii: S0090-4295(17)30046.
    Abstract    

    Abstract available

  147. PAK JS, Lee JJ, Bilal K, Finkelstein M, et al
    Utilization Trends and Short-Term Outcomes of Robotic Versus Open Radical Cystectomy for Bladder Cancer.
    Urology. 2017 Feb 8. pii: S0090-4295(17)30124.
    Abstract    

    Abstract available

  148. MATSUO T, Miyata Y, Asai A, Sagara Y, et al
    Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
    PLoS One. 2017;12:e0171091.
    Abstract    

    Abstract available

  149. XIONG Y, Li J, Ma S, Ge J, et al
    A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
    PLoS One. 2017;12:e0170819.
    Abstract    

    Abstract available

  150. SHIN SS, Song JH, Hwang B, Noh DH, et al
    HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation.
    PLoS One. 2017;12:e0171860.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;